Study on Efficacy of Attenuated Zoster Vaccine, Live

Herpes Zoster Clinical Trial

Official title:

Evaluation of the Efficacy of Attenuated Zoster Vaccine, Live From Herpes Zoster in Adults Aged 40 Years or older---a Multicenter, Randomized, Double-blinded,Placebo-controlled Trial Phase III

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04334577
• Other study ID #: F20190717
• Status: Completed
• Phase: Phase 3
• Start date: April 20, 2020
• Est. completion date: July 18, 2021

Study information

• Verified date: December 2021
• Source: Changchun BCHT Biotechnology Co.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Varicella-zoster virus (VZV) is a herpesvirus that causes two distinct clinical syndromes. Primary infection is manifested as varicella (chickenpox) , whereas reactivation of latent VZV results in a localized eruption known as herpes zoster. The investigational vaccine of this study is produced by Changchun BCHT biotechnology Co. It's a live attenuated herpes zoster vaccine based on the production process of live attenuated chickenpox vaccine.This study plans to have 25000 adults aged 40 years or older and involves in a randomized, double-blind, placebo-controlled trial . The primary outcome is to evaluate the efficacy of the vaccine against herpes zoster 30 days after vaccination and the safety of the vaccine.

Description:

Varicella-zoster virus (VZV) is a herpesvirus that causes two distinct clinical syndromes. Primary infection is manifested as varicella (chickenpox) , whereas reactivation of latent VZV results in a localized eruption known as herpes zoster. The investigational vaccine of this study is produced by Changchun BCHT biotechnology Co. It's a live attenuated herpes zoster vaccine based on the production process of live attenuated chickenpox vaccine.This study plans to have 25000 adults aged 40 years or older and involves in a randomized, double-blind, placebo-controlled trial . The primary outcome is to evaluate the efficacy of the vaccine against herpes zoster 30 days after vaccination and the safety of the vaccine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25000
• Est. completion date: July 18, 2021
• Est. primary completion date: July 18, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• 01 Healthy volunteers aged 40 years or older;

• 02 Able to understand and give informed consent;.

• 03 Able to comply with requirements of all clinical trial protocol for completing the study;

• 04 Axillary temperature =37.0 at the time of enrollment;

Exclusion Criteria:

• 05 History of herpes zoster;

• 06 History of vaccination against herpes zoster or varicella ;

• 07 Allergic sensitivity to any of the components (including neomycin) in the study vaccine and a history of severe allergies to other vaccine;

• 08 Premenopausal with positive pregnancy test, pregnant or lactating female, or female planning to become pregnant within 6 months;

• 09 Subjects with congenital history of immunity deficiency (e.g., primary immunoglobulin deficiency, isolated IgA deficiency, etc.) or family history;

• 10 Receipt of immunoglobulins and/or any blood products within the 5 months preceding of study vaccine or planning to receive these products during the study period;

• 11 Immunosuppression resulting from disease,such as immunodeficiency, malignant tumor, HIV infection, organ and bone marrow transplantation, leukemia, lymphoma, Hodgkin's disease caused by low immunity; Receipt of immunosuppressive therapy with corticosteroids (except intermittent topical or inhaled corticosteroids [< 800 g/ d Beclomethasone or equivalent]); Other immunosuppressive/cytotoxic treatments (cancer chemotherapy or organ transplantation);

• 12 Subjects with acute infections (such as mumps, etc.), chronic infections in the acute phase (such as active untreated tuberculosis, etc.) or any advanced immune disease;

• 13 Use of any investigational or non-registered product (drug, biological product or device) other than the study vaccine within 1 month before study vaccination , or planed use during the study period;

• 14 Administration or planned administration of any other immunizations within 1 month before study vaccination or scheduled within the study period after study vaccination.

• 15 Any non-local antiviral active treatment within 1 month prior to vaccination, including but not limited to acyclovir, famciclovir, valacyclovir and ganciclovir;

• 16 Taking certain pharmaceuticals to be like salicylate kind, including aspirin, and diflunisal, or going to take these medicine during the study period.

• 17 history of thrombocytopenia or coagulation disorders that may cause subcutaneous injection contraindications;

• 18 significant diseases or significant underlying diseases (such as pulmonary heart disease, pulmonary edema, hypertension that cannot be effectively controlled with drugs [systolic blood pressure =160 mmHg, diastolic blood pressure =100 mmHg] that may interfere with or hinder the completion of the study, serious liver and kidney diseases, diabetes with concurrent symptoms, etc.);

• 19 Various infectious, suppurative and allergic skin diseases;

• 20 History of psychiatric and neurological disorders (e.g., depression, epilepsy or convulsion);

• 21 Any other conditions may compromise the safety or availability of participants in the judgment of the investigator.(e.g., malleable psoriasis, chronic pain syndrome, cognitive impairment, severe hearing loss, and other conditions that may interfere with study evaluation).

Related Conditions & MeSH terms

• Herpes Zoster

Intervention

Biological:
• live attenuated zoster vaccine
subcutaneous injection
• placebo
subcutaneous injection

Locations

Country	Name	City	State
China	Zhejiang Provincial Center for Disease Control and Prevention	Hanzhou	Zhejiang
China	Jiangsu Province Center for Disease Control and Prevention	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Changchun BCHT Biotechnology Co.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The incidence of postherpetic neuralgia (PHN)30 days to 13 months after vaccination	The incidence of postherpetic neuralgia (PHN)diagnosed 30 days to 13 months after vaccination	30 days -13 months after the vaccination
Primary	The incidence of herpes zoster 30 days to 13 months after vaccination	The incidence of herpes zoster diagnosed in participants 30 days to 13 months after vaccination	30 days - 13 months after the vaccination
Secondary	The incidence of herpes zoster after vaccination	The incidence of herpes zoster diagnosed in participants after vaccination.	0 day-13 months after the vaccination
Secondary	The incidence of laboratory-confirmed herpes zoster 30 days to 13 months after vaccination	The incidence of laboratory-confirmed herpes zoster diagnosed in participants 30 days to 13 months after vaccination.	30 days- 13 months after the vaccination
Secondary	Occurrence of solicited adverse reactions after the vaccination	Occurrence of solicited adverse reactions within 14 days after the vaccination.	within 14 days after the vaccination
Secondary	Occurrence of adverse reactions after the vaccination.	Occurrence of adverse reactions within 42 days after the vaccination.	within 42 days after the vaccination
Secondary	Occurrence of severe adverse reactions after the vaccination	Occurrence of severe adverse reactions within 13 months after the vaccination	within 13 months after the vaccination
Secondary	Geometric mean titre of serum for antibody responses 42 days post-vaccination	Geometric mean titre of Serum for antibody responses at day 42 post-vaccination	42 days after the vaccination
Secondary	Geometric mean fold increase of serum for antibody responses 42 days post-vaccination	Geometric mean fold increase of Serum for antibody responses at day 42 post-vaccination	42 days after the vaccination
Secondary	Four-fold increase rate of serum for antibody responses 42 days post-vaccination	Four-fold increase rate of Serum for antibody responses at 42 day post-vaccination	42 days after the vaccination
Secondary	Geometric mean titre of serum for antibody responses 6 months post-vaccination	Geometric mean titre of Serum for antibody responses at 6 months post-vaccination	6 months after the vaccination
Secondary	Geometric mean fold increase of serum for antibody responses 6 months post-vaccination	Geometric mean fold increase of Serum for antibody responses at 6 months post-vaccination	6 months after the vaccination
Secondary	Four-fold increase rate of serum for antibody responses 6 months post-vaccination	Four-fold increase rate of Serum for antibody responses at 6 months post-vaccination	6 months after the vaccination
Secondary	Geometric mean titre of serum for antibody responses 13 months post-vaccination.	Geometric mean titre of Serum for antibody responses at 13 months post-vaccination	13 months after the vaccination
Secondary	Geometric mean fold increase of serum for antibody responses 13 months post-vaccination.	Geometric mean fold increase of Serum for antibody responses at 13 months post-vaccination	13 months after the vaccination
Secondary	Four-fold increase rate of serum for antibody responses 13 months post-vaccination.	Four-fold increase rate of Serum for antibody responses at 13 months post-vaccination	13 months after the vaccination